ANIP News and Press, ANI Pharmaceuticals Inc. From 10/01/21

The following slide deck was published by ANI Pharmaceuticals, Inc. in conjunction with this event. For further details see: ANI Pharmaceuticals (ANIP) Investor Presentation - Slideshow

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021 as follows: ...

-- Current annual market for reference listed drug (“RLD”) Bystolic® totals more than $1 billion -- -- Simultaneous launch from two manufacturing sites -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today a...

-- Prescription Drug User Fee Act (“PDUFA”) target action date is October 29, 2021 -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq:ANIP) today announced that the Company’s supplemental New Drug Application (“s...

Image source: The Motley Fool. ANI Pharmaceuticals, inc (NASDAQ: ANIP) Q2 2021 Earnings Call Aug 6, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: ANI Pharmaceuticals, inc (ANIP) Q2 2021 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (ANIP) Q2 2021 Earnings Conference Call August 6, 2021 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Nikhil Lalwani – President and Chief Executive Officer Steve Carey – Chief Financial Officer Conference Call Participants Elli...

-- Second quarter 2021 net revenues of $48.6 million; net loss of $14.1 million and diluted loss per share of ($1.17) -- -- Second quarter adjusted non-GAAP EBITDA of $13.1 million and adjusted non-GAAP diluted earnings per share of $0.67 -- -- Refiled supplemental...

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2021 financial results on Friday, August 6, 2021. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Care...

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company has re-filed its supplemental new drug application (“sNDA”) for Cortrophin ® Gel with the U.S. Food and Drug Administration (“...

ANI's business growth rate could be on the cusp of a rapid acceleration. Free cash flow generation is on the upswing. Stock valuations are pricing in stagnant results, mimicking rear-view mirror thinking. I like the technical chart pattern - a rising price could launch the quo...